Study of Nerve Excitability Changes in Adults with Cisplatin-Induced Peripheral Neuropathy Using Specialized Nerve Tests

What this Trial Is About

Researchers are evaluating nerve excitability changes in people with peripheral neuropathy caused by cisplatin chemotherapy. The study focuses on understanding how nerve function changes in this condition and aims to find early signs of nerve damage in patients receiving cisplatin-based chemotherapy. This investigation uses a specialized nerve conduction test called threshold tracking nerve conduction studies TTNCS to better understand the nerve problems linked to this treatment. Participants are divided into two groups one group includes people who have not yet been treated with cisplatin but are about to start, and the other group includes those who have already received cisplatin and are experiencing neuropathy symptoms. Group A will have multiple visits including baseline and follow-up neurological exams and conduction studies, phone call check-ins during chemotherapy, and additional testing if symptoms develop. Group B will have a one-time visit with neurological exams and conduction studies to assess existing symptoms. During the study, participants will undergo neurological exams, nerve conduction tests using a non-invasive device that applies electrical stimuli to specific nerves, blood tests, and complete questionnaires about symptoms. Researchers will measure changes in nerve excitability compared to baseline and track the development of neuropathy symptoms over time. Safety and symptom progression will be monitored closely through scheduled visits and phone calls. The study expects to enroll about 60 participants and will run until December 2028.

Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy